TECHNOLOGY/BUSINESS OPPORTUNITY Modified cyclodextrins to counteract the effects... Tender

Procurement Summary

Country : USA

Summary : TECHNOLOGY/BUSINESS OPPORTUNITY Modified cyclodextrins to counteract the effects of fentanyl and related opioids

Deadline : 12 Apr 2025

Other Information

Notice Type : Tender

TOT Ref.No.: 116219684

Document Ref. No. : IL-13067

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

Description

Opportunity:

Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract no. DE-AC52-07NA27344 (Contract 44) with the U.S. Department of Energy (DOE), is offering the opportunity to enter into a collaboration to further develop and commercialize its modified cyclodextrins to counteract the effects of fentanyl and related opioids.



Background:

Fentanyl is a powerful rapid-acting opioid used to treat patients to reduce their pain. It is 50 to 100 times more potent than morphine and heroin and according to the DEA is now the leading cause of death for Americans between the ages of 18 and 45. Due to this largely recognized fentanyl epidemic, there is a great need for treatment to counteract the effects of fentanyl for overdose cases.

Cyclodextrins (CDs), which are sugar molecules bound together in rings of various sizes, have been shown to be capable of sequestering fentanyl and its analogues. By binding to the fentanyl with its hollow central cavity, CDs can reduce its bioavailability, thus neutralizing the effects of the drug. Optimization of the central cavity of the cyclodextrin molecule is required for the binding of the fentanyl to be successful. For example, FDA approved drug, sugammadex, was found to bind to another drug rocuronium effectively, but with fentanyl, the affinity was relatively low. This was due to its large interior cavity that did not allow the opioid molecule to fit tightly within.

To optimize the affinity for fentanyl, LLNL researchers used a combined experimental and computational approach to screen for modified cyclodextrins that have suitable characteristics like appropriately sized central cavity that could enhanced their affinities for fentanyl and related analogues.



Description:

After screening at least 50 different cyclodextrins, LLNL researchers found that the drug Subetadex shows enhanced affinities for fentanyl an...
Active Contract Opportunity
Notice ID : IL-13067
Related Notice
Department/Ind. Agency : ENERGY, DEPARTMENT OF
Sub-tier : ENERGY, DEPARTMENT OF
Office: LLNS – DOE CONTRACTOR
General Information
Contract Opportunity Type: Special Notice (Original)
Original Published Date: Mar 12, 2025 07:29 am PDT
Original Response Date: Apr 12, 2025 11:00 am PDT
Inactive Policy: 15 days after response date
Original Inactive Date: Apr 27, 2025
Initiative:
Classification
Original Set Aside:
Product Service Code:
NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing

Place of Performance: Livermore, CA USA

Documents

 Tender Notice